Australia Eastern Europe Western Europe Africa Middle East South America Asia Central America North America
All India
Product Description
CANMAb(TM) 440 mg Injection which contains trastuzumab used for the treatment of HER2-positive metastatic breast cancer in India. CANMAb(TM), developed jointly by Biocon Pharma and Mylan under a global partnership, is being introduced for the benefit of patients in India. Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb(TM) will offer a high quality, more affordable option to breast cancer patients in India.